P551: A PHASE 3, RANDOMIZED, OPEN‐LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE IN PREVIOUSLY UNTREATED PATIENTS WITH TP53‐MUTANT ACUTE MYELOID LEUKEMIA

Saved in:
Bibliographic Details
Published in:HemaSphere 2022-06, Vol.6, p.450-451
Main Authors: Daver, N. G., Vyas, P., Chao, M. P., Xing, G., Renard, C., Ramsingh, G., Sallman, D. A., Wei, A. H.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 451
container_issue
container_start_page 450
container_title HemaSphere
container_volume 6
creator Daver, N. G.
Vyas, P.
Chao, M. P.
Xing, G.
Renard, C.
Ramsingh, G.
Sallman, D. A.
Wei, A. H.
description
doi_str_mv 10.1097/01.HS9.0000845092.62208.b7
format article
fullrecord <record><control><sourceid>wiley_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_d7f4b915802d46b592cb2753b77d902d</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_d7f4b915802d46b592cb2753b77d902d</doaj_id><sourcerecordid>HEM3BF03806</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2740-51b33f1d1d7faf88908ebb0259930ae9e7bae2d0651d23916f55d773753bb1743</originalsourceid><addsrcrecordid>eNqVkctu1DAUhiMEElXpO1ism8GXOI678ySeiUVumjhF042VTBw6JWiqZFDVHY_Ae_EWPAlupwK2eGPr-HzfOdLvee8RXCDI2QeIFmnNF9CdKKCQ40WIMYwWHXvlnWHKsM9xgF7_837rXczznetHnPMQszPvZ0UpugICVKmoJSCXYCOKpMzVjUwuQVnJ4tf3H5lYygzUukm2QF6LrBFaFWugUwlqsZJ6CxwD5GqlYhFvQbkCuVhvykzlYglUAeIyX6rCQWUBPimdAnEjYqVVogr59F9t5LUqmzrbgqbQGym0TEDl-mWh6xOhK0rcJnmjRaGBiBstQb6VWakSkMnmo8yVeOe9Gdpxthcv97nXuOXi1M_Ktdss83eYBdCnqCNkQD3q2dAOUcRhZLsOYso5ga3llnWtxT0MKeox4SgcKO0ZI4ySrkMsIOeeOnn7Q3tn7qf913Z6NId2b54Lh-mzaafjfjda40YEHUc0grgPwo5yvOvwk4ixnruac12dXLvpMM-THf74EDRPKRuIjEvZ_E3ZPKdsOubg4AQ_HMajneYv47cHO5lb247HWwMxREGAuI-hA0IIiQ-hMzgsfsH2o338j4EmlTlZriCJYEh-A6bPr3Y</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>P551: A PHASE 3, RANDOMIZED, OPEN‐LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE IN PREVIOUSLY UNTREATED PATIENTS WITH TP53‐MUTANT ACUTE MYELOID LEUKEMIA</title><source>PubMed (Medline)</source><source>Wiley Open Access</source><creator>Daver, N. G. ; Vyas, P. ; Chao, M. P. ; Xing, G. ; Renard, C. ; Ramsingh, G. ; Sallman, D. A. ; Wei, A. H.</creator><creatorcontrib>Daver, N. G. ; Vyas, P. ; Chao, M. P. ; Xing, G. ; Renard, C. ; Ramsingh, G. ; Sallman, D. A. ; Wei, A. H.</creatorcontrib><identifier>ISSN: 2572-9241</identifier><identifier>EISSN: 2572-9241</identifier><identifier>DOI: 10.1097/01.HS9.0000845092.62208.b7</identifier><language>eng</language><publisher>Philadelphia, PA: Lippincott Williams &amp; Wilkins</publisher><ispartof>HemaSphere, 2022-06, Vol.6, p.450-451</ispartof><rights>Copyright © 2022 The Author(s).</rights><rights>Lippincott Williams &amp; Wilkins</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1097%2F01.HS9.0000845092.62208.b7$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1097%2F01.HS9.0000845092.62208.b7$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,11542,27903,27904,46031,46455</link.rule.ids></links><search><creatorcontrib>Daver, N. G.</creatorcontrib><creatorcontrib>Vyas, P.</creatorcontrib><creatorcontrib>Chao, M. P.</creatorcontrib><creatorcontrib>Xing, G.</creatorcontrib><creatorcontrib>Renard, C.</creatorcontrib><creatorcontrib>Ramsingh, G.</creatorcontrib><creatorcontrib>Sallman, D. A.</creatorcontrib><creatorcontrib>Wei, A. H.</creatorcontrib><title>P551: A PHASE 3, RANDOMIZED, OPEN‐LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE IN PREVIOUSLY UNTREATED PATIENTS WITH TP53‐MUTANT ACUTE MYELOID LEUKEMIA</title><title>HemaSphere</title><issn>2572-9241</issn><issn>2572-9241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>DOA</sourceid><recordid>eNqVkctu1DAUhiMEElXpO1ism8GXOI678ySeiUVumjhF042VTBw6JWiqZFDVHY_Ae_EWPAlupwK2eGPr-HzfOdLvee8RXCDI2QeIFmnNF9CdKKCQ40WIMYwWHXvlnWHKsM9xgF7_837rXczznetHnPMQszPvZ0UpugICVKmoJSCXYCOKpMzVjUwuQVnJ4tf3H5lYygzUukm2QF6LrBFaFWugUwlqsZJ6CxwD5GqlYhFvQbkCuVhvykzlYglUAeIyX6rCQWUBPimdAnEjYqVVogr59F9t5LUqmzrbgqbQGym0TEDl-mWh6xOhK0rcJnmjRaGBiBstQb6VWakSkMnmo8yVeOe9Gdpxthcv97nXuOXi1M_Ktdss83eYBdCnqCNkQD3q2dAOUcRhZLsOYso5ga3llnWtxT0MKeox4SgcKO0ZI4ySrkMsIOeeOnn7Q3tn7qf913Z6NId2b54Lh-mzaafjfjda40YEHUc0grgPwo5yvOvwk4ixnruac12dXLvpMM-THf74EDRPKRuIjEvZ_E3ZPKdsOubg4AQ_HMajneYv47cHO5lb247HWwMxREGAuI-hA0IIiQ-hMzgsfsH2o338j4EmlTlZriCJYEh-A6bPr3Y</recordid><startdate>20220623</startdate><enddate>20220623</enddate><creator>Daver, N. G.</creator><creator>Vyas, P.</creator><creator>Chao, M. P.</creator><creator>Xing, G.</creator><creator>Renard, C.</creator><creator>Ramsingh, G.</creator><creator>Sallman, D. A.</creator><creator>Wei, A. H.</creator><general>Lippincott Williams &amp; Wilkins</general><general>Wiley</general><scope>24P</scope><scope>WIN</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>DOA</scope></search><sort><creationdate>20220623</creationdate><title>P551: A PHASE 3, RANDOMIZED, OPEN‐LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE IN PREVIOUSLY UNTREATED PATIENTS WITH TP53‐MUTANT ACUTE MYELOID LEUKEMIA</title><author>Daver, N. G. ; Vyas, P. ; Chao, M. P. ; Xing, G. ; Renard, C. ; Ramsingh, G. ; Sallman, D. A. ; Wei, A. H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2740-51b33f1d1d7faf88908ebb0259930ae9e7bae2d0651d23916f55d773753bb1743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Daver, N. G.</creatorcontrib><creatorcontrib>Vyas, P.</creatorcontrib><creatorcontrib>Chao, M. P.</creatorcontrib><creatorcontrib>Xing, G.</creatorcontrib><creatorcontrib>Renard, C.</creatorcontrib><creatorcontrib>Ramsingh, G.</creatorcontrib><creatorcontrib>Sallman, D. A.</creatorcontrib><creatorcontrib>Wei, A. H.</creatorcontrib><collection>Wiley Open Access</collection><collection>Wiley Online Library Free Content</collection><collection>CrossRef</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>HemaSphere</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Daver, N. G.</au><au>Vyas, P.</au><au>Chao, M. P.</au><au>Xing, G.</au><au>Renard, C.</au><au>Ramsingh, G.</au><au>Sallman, D. A.</au><au>Wei, A. H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P551: A PHASE 3, RANDOMIZED, OPEN‐LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE IN PREVIOUSLY UNTREATED PATIENTS WITH TP53‐MUTANT ACUTE MYELOID LEUKEMIA</atitle><jtitle>HemaSphere</jtitle><date>2022-06-23</date><risdate>2022</risdate><volume>6</volume><spage>450</spage><epage>451</epage><pages>450-451</pages><issn>2572-9241</issn><eissn>2572-9241</eissn><cop>Philadelphia, PA</cop><pub>Lippincott Williams &amp; Wilkins</pub><doi>10.1097/01.HS9.0000845092.62208.b7</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2572-9241
ispartof HemaSphere, 2022-06, Vol.6, p.450-451
issn 2572-9241
2572-9241
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_d7f4b915802d46b592cb2753b77d902d
source PubMed (Medline); Wiley Open Access
title P551: A PHASE 3, RANDOMIZED, OPEN‐LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE IN PREVIOUSLY UNTREATED PATIENTS WITH TP53‐MUTANT ACUTE MYELOID LEUKEMIA
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T15%3A01%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P551:%20A%20PHASE%203,%20RANDOMIZED,%20OPEN%E2%80%90LABEL%20STUDY%20EVALUATING%20THE%20SAFETY%20AND%20EFFICACY%20OF%20MAGROLIMAB%20IN%20COMBINATION%20WITH%20AZACITIDINE%20IN%20PREVIOUSLY%20UNTREATED%20PATIENTS%20WITH%20TP53%E2%80%90MUTANT%20ACUTE%20MYELOID%20LEUKEMIA&rft.jtitle=HemaSphere&rft.au=Daver,%20N.%20G.&rft.date=2022-06-23&rft.volume=6&rft.spage=450&rft.epage=451&rft.pages=450-451&rft.issn=2572-9241&rft.eissn=2572-9241&rft_id=info:doi/10.1097/01.HS9.0000845092.62208.b7&rft_dat=%3Cwiley_doaj_%3EHEM3BF03806%3C/wiley_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2740-51b33f1d1d7faf88908ebb0259930ae9e7bae2d0651d23916f55d773753bb1743%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true